AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05346432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS23
Description: PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
Study NCT05592834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive deviance hearth strategy
Description: The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value.
Study NCT06673225 — intervention group
Intervention type: OTHER
Intervention: Analysis of results
Description: Analysis of previous imaging and/or laboratory tests, vital signs, body composition, pulmonary function, peripheral muscle strength, calf circumference, nutritional risk, quality of life, frailty level, and anxiety and depression. Screening for respiratory diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, and other lung lesions, is based on spirometry and thoracic radiological images after the health professional's examination. After the multiprofessional procedures, patients will be evaluated by a physician to start specific treatment and/or perform complementary exams if necessary. Every year, they will be re-evaluated to record acute exacerbations of chronic respiratory diseases and assess disease progression through spirometry and thoracic radiological images.
Study NCT06672120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Combined, home-based, supervised, video- assisted, endurance and resistance training
Study NCT05592834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent facilitator trainings
Description: Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
Study NCT05592834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive neither the PD nor the PFT interventions but care as usual
Study NCT06671223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration
Description: The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
Study NCT06671223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: The control group is used to compare the effectiveness of infiltrations with a non-invasive approach in the treatment of plantar fasciopathy. This group will not receive any infiltration and will focus on conservative interventions.
Study NCT06671574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional intelligence and Relaxation techniques
Description: In each session, participants will engage in exercises aimed at recognizing, understanding, and regulating their emotions. These interactive activities will foster personal reflection and group discussion, helping individuals identify emotions in various situations and their impact on behavior. This approach will enhance emotional awareness and equip participants with practical tools for managing stress and anxiety. Various relaxation techniques will also be introduced. Deep breathing exercises will teach participants to calm their minds and bodies, reducing tension. Guided meditation will help them focus inward, promoting mental peace and deep relaxation. Additionally, visualization exercises will encourage imagining calming scenarios, alleviating anxiety and improving overall well-being.
Study NCT06672770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises
Study NCT06672770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Inspiratory Muscle Training
Description: The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
Study NCT06671327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive Dexmedetomidine injection
Description: The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
Study NCT06671327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: The Placebo group was infused with equal amounts of isochronous normal saline.
Study NCT04773041 — intervention group
Intervention type: PROCEDURE
Intervention: Infinitome
Description: All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
Study NCT06113666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
Description: dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
Study NCT06113666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital patient education about insomnia (PE)
Description: Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts and tips of the day (within app)
Description: Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasts and tips of the day (within app)
Description: Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLIFE app (self-regulation features)
Description: Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mLIFE app (self-regulation features)
Description: Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
Study NCT04714060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: mAb by SC administration
Study NCT04710823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
Study NCT06385990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTD1
Description: UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Study NCT04710823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
Study NCT04968054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm I (Propofol)
Description: Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
Study NCT04968054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm II (Remimazolam)
Description: Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
Study NCT06168760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric Measurements
Description: Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
Study NCT04733378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-operative neurological monitoring
Description: Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
Study NCT05472454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ready-to-eat meals
Description: Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
Study NCT04689815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Arsenic Trioxide Formulation
Description: Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
Study NCT05042388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)
Description: Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
Study NCT05042388 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
Study NCT05988697 — intervention group
Intervention type: DRUG
Intervention: Combind asprin with Trametinib and Dabrafenib
Description: Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
Study NCT06256120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Restrictive
Description: 3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
Study NCT06256120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liberal
Description: 7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLIFE app (social support features)
Description: The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors.
Study NCT05176847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard mLIFE app (social support features)
Description: The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.
Study NCT05925959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Weight Management Program
Description: The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
Study NCT06396156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior enclavation
Description: Anterior enclavation of iris-claw lens
Study NCT06396156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior enclavation
Description: Posterior enclavation of iris-claw lens
Study NCT04509102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR
Description: Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
Study NCT04509102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
Study NCT06561971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study NCT05851105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α-globin restored autologous hematopoietic stem cells
Description: α-globin restored autologous hematopoietic stem cells modified with LentiHBA T>C
Study NCT05651568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized resistance training
Description: It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session.
Study NCT05651568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected).
Study NCT05956379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, >=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
Study NCT04518657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for Physical Activity in MS (BIPAMS)
Description: A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
Study NCT04518657 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness for MS (WellMS)
Description: A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
Study NCT05836779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: CBL-514 will be administered at the raised area of cellulite.
Study NCT05065775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
Study NCT05257551 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention